[NCI CIRB] EA8191: Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)

Principal Investigator

Arthur Hung

Study Purpose

This study is being done to answer the following question:
Can PET/CT scans help provide more tailored treatment recommendations and outcomes for men who have prostate cancer after radical prostatectomy (RP)?
Will adding either more focal or directed radiation treatment and/or more systemic treatment to standard of care treatment help to delay progression of prostate cancer in men who have already had an RP and now have recurrence? We are doing this study because we want to find out if these PET-directed approaches are better or worse than the usual approach for your prostate cancer. The usual approach is defined as care most people get for prostate cancer.

Medical Condition(s)

Prostate cancer

Eligibility Criteria

Participants must be at least 18 years old, male, with evidence of biochemical recurrence (a rise in the blood
level of prostate-specific antigen [PSA]) after radical prostatectomy, and no evidence of metastases on
conventional imaging.

Age Range

18 - 99

Healthy Volunteers Needed


Duration of Participation

You will be assigned to 1 of 4 possible treatment groups depending on the result of your PET/CT scan. The treatment portion of the study will last 6 months. After you finish your study treatment, your doctor will continue to follow your condition for up to 10 years.

Minors Included



Knight Cancer Institute Clinical Trials


ECOG-ACRIN Cancer Research Group and the National Cancer Institute

Recruitment End


Compensation Provided


Go Back